美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Militia Long/Short Equity ETF

27.49

+0.00720.03%

成交量：2.66萬

成交額：72.74萬

市值：- -

市盈率：- -

高：27.49

開：27.40

低：27.25

收：27.48

資料載入中...

總覽公司新聞公告

中國目前唯一獲批肝癌一線雙免疫聯合療法出現，全新患者援助計劃啓動

艾伯維“狙擊”普方生物：專利戰下政策如何助力行業規範？

21世纪经济报道

KRAS G12D先驅都扛不住了

消息：特朗普政府要求移民局追蹤並驅逐無陪伴兒童移民

東方亮，西方不亮：出海管線之殤

DLL3領域的中國時刻

信達生物與奧賽康藥業宣佈第三代EGFR TKI 肺癌靶向藥物奧壹新®（利厄替尼片）獲批上市

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ORR/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":27.4872,"timestamp":1746043200000,"preClose":27.48,"halted":0,"volume":26641,"delay":0,"floatShares":2350000,"shares":0,"eps":0,"marketStatus":"盤前交易","change":0.0072,"latestTime":"05-01 07:15:31 EDT","open":27.4,"high":27.4872,"low":27.25,"amount":727433.745,"amplitude":0.008632,"askPrice":43.7,"askSize":100,"bidPrice":27.01,"bidSize":18,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1746106200000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":27.4872,"sharesOutstanding":2350000,"nav":27.36,"aum":64296000,"bidAskSpread":0,"volumeRatio":0.4329884518797603},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":2350000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.4329884518797603,"shares":0,"dividePrice":0,"high":27.4872,"amplitude":0.008632,"preClose":27.48,"low":27.25,"week52Low":25.63,"pbRate":"--","week52High":28.69,"institutionHeld":0,"latestPrice":27.4872,"committee":-0.694915,"eps":0,"divideRate":0,"volume":26641,"delay":0,"ttmEps":0,"open":27.4,"prevYearClose":25.88,"prevWeekClose":27.8493,"prevMonthClose":27.4872,"prevQuarterClose":27.84,"fiveDayClose":28.129,"twentyDayClose":27.92,"sixtyDayClose":26.9028},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524890141","title":"中國目前唯一獲批肝癌一線雙免疫聯合療法出現，全新患者援助計劃啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2524890141","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524890141?lang=zh_tw&edition=fundamental","pubTime":"2025-04-01 09:35","pubTimestamp":1743471328,"startTime":"0","endTime":"0","summary":"近日，两款肿瘤免疫治疗药物——欧狄沃（纳武利尤单抗注射液）与逸沃（伊匹木单抗注射液）的联合疗法获得中国国家药品监督管理局批准新增适应症，适用于不可切除或晚期肝细胞癌成人患者的一线治疗，成为中国首个且目前唯一获批的肝细胞癌一线双免疫联合疗法。“肝癌在中国的疾病负担尤为沉重，发病人数位居全球第一，每年导致的癌症死亡人数也高居所有癌症第二。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504013361966091.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ORR","BK4097","OS"],"gpt_icon":0},{"id":"2522020873","title":"艾伯維“狙擊”普方生物：專利戰下 政策如何助力行業規範？","url":"https://stock-news.laohu8.com/highlight/detail?id=2522020873","media":"21世纪经济报道","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522020873?lang=zh_tw&edition=fundamental","pubTime":"2025-03-25 18:28","pubTimestamp":1742898487,"startTime":"0","endTime":"0","summary":"继起诉百济神州之后，艾伯维将矛头指向普方生物 。Genmab方面坚决否认上述指控，“艾伯维并未应用该技术开发任何产品，这只是艾伯维近期针对竞争对手提起的多起诉讼中的一起，这些诉讼都是指控艾伯维前员工盗用了其商业机密。”此次艾伯维未对被告方主张或行使任何专利权，而是寻求损害赔偿和广泛的禁令救济。Genmab称将针对艾伯维的诉求积极为公司辩护。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250325201336a6a3670d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250325201336a6a3670d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1267930490.SGD","LU1983299246.USD","LU0256863811.USD","LU0198837287.USD","LU2092937221.SGD","LU1267930573.SGD","IE0002141913.USD","OC","LU1291159041.SGD","LU2468319806.SGD","LU2347655156.SGD","LU0965509283.SGD","LU1929549753.HKD","LU2237443549.SGD","LU2129689431.USD","LU1496350502.SGD","LU0868494617.USD","LU0985320562.USD","BK4588","LU1551013425.SGD","LU1732799900.SGD","LU0861579265.USD","LU0912757837.SGD","LU0310799852.SGD","LU1718418525.SGD","LU2106854487.HKD","LU2112291526.USD","BK4139","OS","LU1989772840.SGD","IE0002270589.USD","IE00BVYPNW00.USD","LU1989772923.USD","LU0234570918.USD","LU1989771016.USD","LU2237443465.HKD","LU0320765646.SGD","LU0256863902.USD","BK4086","ORR","LU0553294199.USD","LU0795875169.SGD","LU2129689605.HKD","LU1003077747.HKD","SG9999001440.SGD","LU1496350171.SGD","BK4550","LU0417517546.SGD","SG9999015952.SGD","ABBV"],"gpt_icon":0},{"id":"2518213795","title":"KRAS G12D先驅都扛不住了","url":"https://stock-news.laohu8.com/highlight/detail?id=2518213795","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518213795?lang=zh_tw&edition=fundamental","pubTime":"2025-03-10 16:17","pubTimestamp":1741594679,"startTime":"0","endTime":"0","summary":"热度持续攀升的KRAS G12D领域，却不断传出糟糕的消息。3月5日，据外媒消息，BMS已经放弃开发KRAS G12D抑制剂MRTX1133，原因是前景堪忧。这并非KRAS G12D赛道的第一个坏消息。如今，随着又一位重磅选手折戟，无疑给KRAS G12D领域敲响了警钟，尤其是对于处在跟随阶段的国内药企来说。很显然，这些国内跟随的选手需要进一步审视其KRAS G12D分子的结构。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/252604","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["ORR"],"gpt_icon":0},{"id":"2513531717","title":"消息：特朗普政府要求移民局追蹤並驅逐無陪伴兒童移民","url":"https://stock-news.laohu8.com/highlight/detail?id=2513531717","media":"联合早报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513531717?lang=zh_tw&edition=fundamental","pubTime":"2025-02-23 22:39","pubTimestamp":1740321574,"startTime":"0","endTime":"0","summary":"美国移民和海关执法局（ICE）的内部备忘录显示，特朗普政府计划扩大针对无陪伴移民儿童的驱逐行动，并要求ICE特工追踪数十万名未成年非法入境者，这些儿童未随父母或合法监护人入境。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"zaobao_highlight","url":"https://www.zaobao.com/realtime/world/story20250223-5920076","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zaobao.com/realtime/world/story20250223-5920076","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zaobao_highlight","symbols":["DNA","HHS","ORR","BK4139","BK4109","BK4009"],"gpt_icon":0},{"id":"2512794661","title":"東方亮，西方不亮：出海管線之殤","url":"https://stock-news.laohu8.com/highlight/detail?id=2512794661","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512794661?lang=zh_tw&edition=fundamental","pubTime":"2025-02-19 17:18","pubTimestamp":1739956689,"startTime":"0","endTime":"0","summary":"海外的临床结果，能否达到中国早期试验的承诺？但很遗憾，结果并不是那么让人满意。最新给出回答的是Corbus Pharmaceuticals。在ASCO泌尿生殖系统癌症研讨会上，Corbus公布了引进自石药集团的Nectin-4 ADC CRB-70第一个西方临床结果。数据公布后，Corbus盘中股价跌幅一度超15%。在该消息的影响下，Elevation单日股价暴跌63.37%。石药集团在中国开展的1期临床，初步ORR是28%；而Corbus在海外开展的1期临床，初步ORR是27%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/251165","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1191","LU1226287792.SGD","LU0880133367.SGD","IE00BZ08YS42.EUR","LU0072913022.USD","LU1951186391.HKD","LU1993786604.SGD","01093","BK1515","LU1960683339.HKD","ORR","LU1226287875.USD","LU1226288170.HKD","BK1521","IE00B543WZ88.USD","LU1226287529.USD","LU0067412154.USD","LU1152091754.HKD","IE00B5MMRT66.SGD","LU1807302812.USD","LU1152091168.USD","LU0140636845.USD","IE00BZ08YR35.GBP","IE00B031HY20.USD","LU1226288253.USD","IE0008368742.USD","LU0326950275.SGD","LU1008478684.HKD","IE0008369823.USD","SG9999004220.SGD","IE00BZ08YT58.USD","LU0501845795.SGD"],"gpt_icon":0},{"id":"2512142249","title":"DLL3領域的中國時刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2512142249","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512142249?lang=zh_tw&edition=fundamental","pubTime":"2025-02-17 16:37","pubTimestamp":1739781474,"startTime":"0","endTime":"0","summary":"DLL3靶点研究开发已有超20年历史，该领域的FIC药物安进的CD3/DLL3双抗tarlatamab也已经获批上市。中国药企再一次将DLL3靶点的研发，推向了新一轮高潮。2023年11月至今，DLL3领域共有6起超1亿美元的交易，中国药企贡献了3例。这场围绕DLL3靶点的争夺战，正在成为中国创新药崛起的缩影。在DLL3靶点研发领域，引领发展的是海外科学家。从再鼎医药的临床数据公布，再到恒瑞医药、信达生物的接连出海，证明了中国药企在DLL3 ADC领域的搅局能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/250965","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["IE00B66KJ199.SGD","CRS","IE0031619046.USD","BK4006","IE00B7SZL793.SGD","LU2065731478.USD","IE00B19Z4B17.USD","ORR"],"gpt_icon":0},{"id":"2504212978","title":"信達生物與奧賽康藥業宣佈第三代EGFR TKI 肺癌靶向藥物奧壹新®（利厄替尼片）獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2504212978","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504212978?lang=zh_tw&edition=fundamental","pubTime":"2025-01-17 08:00","pubTimestamp":1737072000,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2025年1月17日 /美通社/ -- 信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司，与奥赛康药业今日联合宣布，第三代表皮生长因子受体酪氨酸激酶抑制剂靶向药物奥壹新的新药上市申请获中国国家药品监督管理局批准上市，用于既往经EGFR-TKI治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M突变阳性的局部晚期或转移性非小细胞肺癌成人患者治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4598259_ZH98259_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","PFS","BK1583","BK4570","BK4139","PPI","BK4211","IVBIY","LU1969619763.USD","LU2328871848.SGD","LU2488822045.USD","01801","ORR","BK4195","BK1589"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{}}}